|
Video: What is a Stock Split?
|
|
Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy. According to our Xenon Pharmaceuticals stock split history records, Xenon Pharmaceuticals has had 0 splits. | |
|
Xenon Pharmaceuticals (XENE) has 0 splits in our Xenon Pharmaceuticals stock split history database.
Looking at the Xenon Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Xenon Pharmaceuticals shares, starting with a $10,000 purchase of XENE, presented on a split-history-adjusted basis factoring in the complete Xenon Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/07/2014 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$13.29 |
|
End price/share: |
$39.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
197.22% |
|
Average Annual Total Return: |
12.20% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$29,731.72 |
|
Years: |
9.47 |
|
|
|
|
|